Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
about
The clinical implications of gene mutations in chronic lymphocytic leukaemiaBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaRole of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsTargeted therapies in CLL: mechanisms of resistance and strategies for managementTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.Using high-sensitivity sequencing for the detection of mutations in BTK and PLCĪ³2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitorsChanges in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemiaPharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaPrognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemiaSpecificity and biologic activities of novel anti-membrane IgM antibodiesTreatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.Initial treatment of CLL: integrating biology and functional status.Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaMolecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyDetection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Chronic lymphocytic leukemia therapy: new targeted therapies on the wayDisseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib.Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patientsLeukemia cutis in a patient with chronic lymphocytic leukemia presenting as bilateral helical nodules.Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cellsIbrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrationsSpotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia.Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.Emerging immunological drugs for chronic lymphocytic leukemia.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Ibrutinib in B lymphoid malignancies.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
P2860
Q26749214-F1AACF41-ED46-4A95-9AD4-28F45EFB805FQ26765624-B19D3D7F-13D1-4B1A-A549-DC0242BAD7B8Q26775506-649C89A4-9FDC-434D-A755-E639EFA9246AQ26781895-723C3EE8-8B94-4F3D-80C0-A617CA032F9EQ26795594-3AA5616F-F2F8-405F-AF3E-7BF5E2DDCC34Q27002528-73C90806-C9A4-4722-ABB0-ED6A4058003EQ27025812-77994D4E-5035-4388-8B7B-8CB28F1ACFB2Q28075504-DF62BC93-5BD8-40F8-AD87-795DFE2D124BQ30243968-B4B0DE57-4974-4C01-81A7-BEF564D0A353Q30252869-202E3D0B-6B10-4F38-8378-219988E3C444Q31097476-073DB545-65ED-487C-BFB4-8C08E216077BQ33566747-B720E6A5-E336-49E2-856C-EADC42FA3D91Q33798525-9FB470CB-4A1B-4652-967F-896D0C473BE6Q35794593-BA4423B1-43AA-4497-83B3-76414B799211Q35958056-9F562AAE-336D-4BD3-8D44-F364DCCF5A33Q36022532-21815659-1E56-458C-B21C-F6C3CC2BF8FEQ36161658-88FB2233-5D1A-422D-974D-17946F226E29Q36172601-55E0F342-A625-46F7-9EDB-354A4D151590Q36219647-97DF1299-9119-4554-A892-C57012B31187Q36253983-D472AE0C-4354-45B8-B915-80053E679DFBQ36337598-FE236D46-1636-483D-BCFC-9D7086795341Q36437030-EB083087-1CD2-45A2-A427-E1388E1D56FEQ36490049-AA52AFA4-3BBC-4B4E-B38E-27AE4CC02DAFQ36550468-24A9D71D-1D55-48CF-A95B-E2A33D5688F5Q36759124-8452111F-7A70-4BF5-8813-4C7065445B82Q36799831-200E806E-5D7D-4445-B4FD-5B1AEBF6850DQ37113544-4C876AA0-5F90-44CA-A23F-F2D9E36C99E8Q37290270-82CE162B-330F-4CBA-BA2A-CD6EBEC742E4Q37489992-38227A66-090A-4034-9748-ECF2A75540C4Q37641245-6CB01746-523A-4B0F-92F1-77D6685B00D7Q37641736-B906E5A2-9817-4025-B212-1E71A6BD0C13Q37688589-5733BF8E-A52F-43FB-A654-C8509494C176Q37697093-BC378F70-A77D-4230-963D-C3F11CA7FE45Q37742056-F365CF23-BF64-4FB9-B486-01FAAD3DB60FQ38524270-567399F0-A316-4792-8BDC-657DE162612BQ38543771-072BAAF8-2DC2-448B-8319-F9CEE71799C7Q38544216-5131FDAF-AA9F-4744-9A77-329A41AFA426Q38545545-40E5A365-D235-4FFA-A590-629351DA4BD2Q38550810-E7751FE9-9BAA-4C47-B551-32F554D84B08Q38594364-A6DFCC02-6ADD-4514-BD22-F63C2B9FA5D6
P2860
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
description
2014 nĆ® lÅ«n-bĆ»n
@nan
2014 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Ō“Õ„ÕÆÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2014 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ¤Õ„ÕÆÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2014幓ć®č«ę
@ja
2014幓č«ę
@yue
2014幓č«ę
@zh-hant
2014幓č«ę
@zh-hk
2014幓č«ę
@zh-mo
2014幓č«ę
@zh-tw
2014幓č®ŗę
@wuu
name
Ibrutinib for previously untre ...... : a phase 2, single-arm trial.
@ast
Ibrutinib for previously untre ...... : a phase 2, single-arm trial.
@en
type
label
Ibrutinib for previously untre ...... : a phase 2, single-arm trial.
@ast
Ibrutinib for previously untre ...... : a phase 2, single-arm trial.
@en
prefLabel
Ibrutinib for previously untre ...... : a phase 2, single-arm trial.
@ast
Ibrutinib for previously untre ...... : a phase 2, single-arm trial.
@en
P2093
P2860
P921
P1433
P1476
Ibrutinib for previously untre ...... : a phase 2, single-arm trial.
@en
P2093
Adrian Wiestner
Andrew Lipsky
Christian H Geisler
Constance Yuan
Diane C Arthur
Gerald Marti
Irina Maric
Jade Jones
Janet Valdez
P2860
P304
P356
10.1016/S1470-2045(14)71182-9
P577
2014-12-31T00:00:00Z